Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Assets (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Current Assets for 7 consecutive years, with $2.0 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets changed N/A year-over-year to $2.0 billion, compared with a TTM value of $2.0 billion through Sep 2025, changed N/A, and an annual FY2024 reading of $1.5 billion, up 152.29% over the prior year.
  • Current Assets was $2.0 billion for Q3 2025 at Avidity Biosciences, up from $1.5 billion in the prior quarter.
  • Across five years, Current Assets topped out at $2.0 billion in Q3 2025 and bottomed at $287.3 million in Q2 2021.
  • Average Current Assets over 5 years is $713.1 million, with a median of $575.0 million recorded in 2023.
  • The sharpest move saw Current Assets dropped 18.8% in 2021, then skyrocketed 152.29% in 2024.
  • Year by year, Current Assets stood at $411.1 million in 2021, then soared by 51.52% to $622.9 million in 2022, then fell by 1.87% to $611.3 million in 2023, then surged by 152.29% to $1.5 billion in 2024, then grew by 27.47% to $2.0 billion in 2025.
  • Business Quant data shows Current Assets for RNA at $2.0 billion in Q3 2025, $1.5 billion in Q4 2024, and $1.3 billion in Q2 2024.